2022
DOI: 10.1016/j.jim.2022.113345
|View full text |Cite
|
Sign up to set email alerts
|

Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 13 publications
(4 citation statements)
references
References 22 publications
(16 reference statements)
0
3
0
Order By: Relevance
“…Few publications address the use of MSD multiplex technology for protein expression in the agriculture biotechnology industry . Nevertheless, there has been widespread use of this technology in the pharmaceutical industry and in clinical research. MSD technology is very sensitive, with ultralow pico-gram level detection limits and a wide dynamic range of five or more orders of magnitude . This is particularly useful when analyzing samples with multiple traits that express trait proteins at widely varying levels.…”
Section: Description Of Techniquesmentioning
confidence: 99%
“…Few publications address the use of MSD multiplex technology for protein expression in the agriculture biotechnology industry . Nevertheless, there has been widespread use of this technology in the pharmaceutical industry and in clinical research. MSD technology is very sensitive, with ultralow pico-gram level detection limits and a wide dynamic range of five or more orders of magnitude . This is particularly useful when analyzing samples with multiple traits that express trait proteins at widely varying levels.…”
Section: Description Of Techniquesmentioning
confidence: 99%
“…Antibody response to nucleocapsid antigen during infection is shown to correlate with seropositivity 9 . Since the emergence of pandemic, 85 different serological test achieved authorization from FDA 11 . However, out of these 85 assays, majority of them are monoplex cut off assays and very few are fully quantitative assays.…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, it is now clear that not all Abs directed toward the Sars-2-CoV spike protein (C SP) are protective, necessitating the visualization of C SP sub-domain reactivity as well as the distribution of Abs across isotypes and toward new emerging variants. Although several platforms have been described to evaluate SARS-CoV-2-reactive Abs including [5][6][7][8][9][10][11][12], few of these methodologies are quantitative, making direct comparisons across platforms or the cohorts targeted in these studies difficult, thereby hampering our ability to define levels of Ab reactive with C SP or subdomains that correlate with protection. Such analyses are becoming increasingly important as SARS-CoV-2 variants resistant to prior vaccine responses continue to emerge [2].…”
Section: Introductionmentioning
confidence: 99%